Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches
Anna Maria Tortorano,Anna Prigitano,Gianluca Morroni,Lucia Brescini,Francesco Barchiesi
DOI: https://doi.org/10.2147/IDR.S274872
2021-12-19
Infection and Drug Resistance
Abstract:Anna Maria Tortorano, 1 Anna Prigitano, 1 Gianluca Morroni, 2 Lucia Brescini, 2, 3 Francesco Barchiesi 2, 4 1 Department of Biomedical Sciences for Health, Università degli Studi di Milano, Milano, Italy; 2 Department of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, Italy; 3 Clinic of Infectious Diseases, Azienda Ospedaliero Universitaria, Ospedali Riuniti Umberto I-Lancisi-Salesi, Ancona, Italy; 4 Clinic of Infectious Diseases, Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy Correspondence: Anna Maria Tortorano Department of Biomedical Sciences for Health, Università degli Studi di Milano, Via Pascal 36, Milano, 20133, Italy Tel +39 02 50315145 Fax +39 02 50315146 Email Candidemia and invasive candidiasis are the most common healthcare-associated invasive fungal infections, with a crude mortality rate of 25– 50%. Candida albicans remains the most frequent etiology, followed by C. glabrata, C. parapsilosis and C. tropicalis . With the exception of a limited number of species (ie: C. krusei, C. glabrata and rare Candida species), resistance to fluconazole and other triazoles are quite uncommon. However, recently fluconazole-resistant C. parapsilosis , echinocandin-resistant C. glabrata and the multidrug resistant C. auris have emerged. Resistance to amphotericin B is even more rare due to the reduced fitness of resistant isolates. The mechanisms of antifungal resistance in Candida (altered drug-target interactions, reduced cellular drug concentrations, and physical barriers associated with biofilms) are analyzed. The choice of the antifungal therapy for candidemia must take into account several factors such as type of patient, presence of devices, severity of illness, recent exposure to antifungals, local epidemiology, organs involvement, and Candida species. The first-line therapy in non-neutropenic critical patient is an echinocandin switching to fluconazole in clinically stable patients with negative blood cultures and azole susceptible isolate. Similarly, an echinocandin is the drug of choice also in neutropenic patients. The treatment duration is 14 days after the first negative blood culture or longer in cases of organ involvement. An early removal of vascular catheter improves the outcome. The promising results of new antifungal molecules, such as the terpenoid derivative ibrexafungerp, the novel echinocandin with an enhanced half-life rezafungin, oteseconazole and fosmanogepix, representative of new classes of antifungals, are discussed. Keywords: candidemia, Candida , antifungal resistance, management of candidemia, novel antifungals Candidemia and invasive candidiasis are the most common healthcare-associated invasive fungal infections. The incidence varies with geographical region and local epidemiology. Analysis of large multicentric surveys reports an overall pooled incidence rate of 3.88 per 100,000 inhabitants per year (range 1.0 to 10.4) with an increasing trend from the 1990s (median 2.18) to the following periods (median 4.67 in the year 2000–2010 and 3.22 in the last decade). 1 This trend may be justified by a progressive increase in high-risk population related to the prolonged survival of critically ill patients and aging population. Most of the episodes are hospital-acquired with a reported incidence of 0.17–2.7 episodes per 1000 discharges, 0.30–4.9 per 10,000 patient days. 2 However, community-acquired candidemia is emerging as a consequence of an increasing use of long-term intravenous devices such as tunneled intravascular and peripherally inserted central catheter (PICC). 3 Despite treatment, mortality remains high: crude mortality rate varied from 25% to 50%, while the attributable mortality rate is estimated around 10–20%. 1,3 Candidemia has a significant economic burden due to the prolonged stay in hospital, mainly in intensive care unit, and the use of expensive antifungal therapy. A mean total cost per patient with candidemia and invasive candidiasis ranging from 157,574 was reported in a systematic review including five studies. 4 Candida albicans is the most frequent cause of candidemia and invasive infections and, although it remains the most common pathogen overall causing these infections, the prevalence of other species has been increasing over time. The SENTRY program analyzing 20,788 invasive isolates collected from 135 medical centers in 39 countries noted a progressive decrease of the frequency of C. albicans from 57.4% in 1997–2001 to 46.4% in 2015–2016 and a parallel increase in C. glabrata, C. parapsil -Abstract Truncated-
pharmacology & pharmacy,infectious diseases